In this section
Following the formation of the NW GLH and implementation of the NHS England National Test Directories for Rare Disease and Cancer, a process of de-duplication of testing across the North West commenced from April 2019. This has resulted in some laboratory processes transferring from the Liverpool laboratory site to the Manchester laboratory site (and vice versa), and some investigations that were previously performed on both sites are now only being performed in one location.
The NW GLH will take responsibility for ensuring samples are transported between sites where necessary for testing and have a courier in place to facilitate this.
Either laboratory will be able to provide information on testing and sample requirements if required.
